Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience

• Published in: Clinical sarcoma research Vol. 4; no. 1; p. 7
• Main Authors: Frezza, Anna Maria, Benson, Charlotte, Judson, Ian R, Litiere, Saskia, Marreaud, Sandrine, Sleijfer, Stefan, Blay, Jean-Yves, Dewji, Raz, Fisher, Cyril, van der Graaf, Winette, Hayward, Larry
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29-07-2014; BioMed Central
• Subjects: Desmoplastic small round cell tumour; Tyrosine kinase inhibitor; Pazopanib
• ISSN: 2045-3329; 2045-3329
• DOI: 10.1186/2045-3329-4-7

We retrospectively reviewed data from nine pre-treated metastatic desmoplastic small round cell tumour (DSRCT) patients who received pazopanib.
Three patients received pazopanib within the EORTC phase II 62043, three in the EORTC phase III 62072, and three in the context of UK named patient program.
Nine patients were retrieved from the databases, the median age was 30 years (range: 21-47), they were all males. All had received prior chemotherapy. At the time of treatment start, 4 patients (44%) had ECOG PS 0, 4 (44%) PS 1, 1 (11%) PS 2. Best response was partial response (PR) in 2/9 (22%) patients, stable disease (SD) in 5/9 (56%) and progressive disease (PD) in 2/9 (22%) with a clinical benefit rate (PR + SD > 12 weeks) of 78%. Median PFS and OS were 9.2 (95%CI: 0-23.2) and 15.4 (95%CI: 1.5-29.3) months respectively. With a median follow-up of 20 months, 2/9 (22%) patients are still alive, all progressed. The most common toxicities included neutropenia (G1-2 45%; G3-4 11%), anaemia (G1-2 45%), fatigue (G1-2 67%), diarrhoea (G1-2 45%; G3-4 11%), nausea (G1-2 45%), hypertension (G1-2 45%) and increase in liver enzymes (G1-2 34%; G3-4 11%). Three patients (34%) required a dose reduction. One of the patients discontinued treatment because of persistent increase in total bilirubin level, one due to patient's choice.
In this series, pazopanib showed interesting activity in DSRCT patients who progressed after prior chemotherapy without major toxicity.